Qutaiba A. Qasim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qutaiba A. Qasim has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Hany Akeel Al-Hussaniy
Department of Pharmacology, College of Pharmacy, Al-nisour University, Baghdad, Iraq
2 shared publications - Abdulrahman A. Almehizia
Drug Exploration and Development Chair (DEDC), Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P. O. Box 2457, Riyadh 11451, Saudi Arabia
1 shared publication - Ahmed Saeed Hamad
Albayan University, Baghdad, Iraq
1 shared publication - Amjad Ibraim Oraibi
Al-Manara College for Medical Sciences, Department of Pharmacy, Amarah, Iraq
1 shared publication - Angham M. Abed
Al Safwa University College, Karbala, Iraq
1 shared publication - Elyor Berdimurodov
Faculty of Chemistry, National University of Uzbekistan, Tashkent, Uzbekistan
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by Pensoft Publishers in Folia Medica
- Vol. 68 (5) , e185886
Monitoring adverse drug reactions of isotretinoin: a prospective observational study
Introduction : Acne vulgaris is very common and may have a significant psychosocial effect. Moderate to severe acne is best treated using oral isotretinoin, which has a wide spectrum of adverse drug reactions (ADRs). Aim : To characterize the occurrence, pattern, and severity of isotretinoin-related ADRs in the Iraqi dermatology clinics and clarify clinical and treatment factors linked to its frequency. Patients and methods : This was a prospective observational cohort study carried out at two of the outpatient dermatology clinics in Basra city between January 2024 and December 2025. Patients were recruited consecutively as they were aged 12 years and older and had been taking systemic isotretinoin as the main form of therapy against acne. Results : Out of 420 patients who were screened, 400 patients qualified. The mean age was 21.8 years, and the SD was 4.7 years; 55% of the population was female, and 90% had moderate or severe acne. In general, 360 patients (90%) had at least one ADR, which led to 965 events. The most common were mucocutaneous reactions (88.5% of patients); then there were laboratory abnormalities (22%) and musculoskeletal complaints (around 15%-16%). Biochemical abnormalities were generally mild to moderate, while clinically significant psychiatric events were rare. Moderate/severe ADRs were independently related to female sex, baseline dyslipidemia, and daily dose ≥0.5 mg/kg/day. Conclusion : With the aid of organized monitoring, risk-specific dosing, and strong pregnancy prevention and counseling measures, isotretinoin may be deployed effectively and in a relatively safe way in the Iraqi dermatology clinics.
- 30 October 2026
- Published by Pensoft Publishers in Folia Medica
- Vol. 68 (5) , e185886
Open AccessMonitoring adverse drug reactions of isotretinoin: a prospective observational study
Introduction : Acne vulgaris is very common and may have a significant psychosocial effect. Moderate to severe acne is best treated using oral isotretinoin, which has a wide spectrum of adverse drug reactions (ADRs). Aim : To characterize the occurrence, pattern, and severity of isotretinoin-related ADRs in the Iraqi dermatology clinics and clarify clinical and treatment factors linked to its frequency. Patients and methods : This was a prospective observational cohort study carried out at two of the outpatient dermatology clinics in Basra city between January 2024 and December 2025. Patients were recruited consecutively as they were aged 12 years and older and had been taking systemic isotretinoin as the main form of therapy against acne. Results : Out of 420 patients who were screened, 400 patients qualified. The mean age was 21.8 years, and the SD was 4.7 years; 55% of the population was female, and 90% had moderate or severe acne. In general, 360 patients (90%) had at least one ADR, which led to 965 events. The most common were mucocutaneous reactions (88.5% of patients); then there were laboratory abnormalities (22%) and musculoskeletal complaints (around 15%-16%). Biochemical abnormalities were generally mild to moderate, while clinically significant psychiatric events were rare. Moderate/severe ADRs were independently related to female sex, baseline dyslipidemia, and daily dose ≥0.5 mg/kg/day. Conclusion : With the aid of organized monitoring, risk-specific dosing, and strong pregnancy prevention and counseling measures, isotretinoin may be deployed effectively and in a relatively safe way in the Iraqi dermatology clinics.
- 13 April 2026
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 50 (16) , 7035-7057
Development and fabrication of a sustainable and recyclable COF-366-LP@Cu modified SPE electrode for the enantioselective electro-carboxylation of 1-phenylethan-1-ols to synthesize ( S )-2-phenylpropanoic acid derivatives under mild reaction conditions
This study presents a novel electrocatalytic system using COF-366 modified with l -proline and coated with Cu to efficiently convert CO 2 into phenylpropanoic acid derivatives under mild conditions, achieving 90–97% yields in 1 hour.
- 13 April 2026
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 50 (16) , 7035-7057
Development and fabrication of a sustainable and recyclable COF-366-LP@Cu modified SPE electrode for the enantioselective electro-carboxylation of 1-phenylethan-1-ols to synthesize ( S )-2-phenylpropanoic acid derivatives under mild reaction conditions
This study presents a novel electrocatalytic system using COF-366 modified with l -proline and coated with Cu to efficiently convert CO 2 into phenylpropanoic acid derivatives under mild conditions, achieving 90–97% yields in 1 hour.
- Open Access
- 28 February 2026
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 15 (3) , e27641
Comparative assessment of kidney function biomarkers related to anti-diabetic medication consumption; a cross-sectional analysis
Introduction: Diabetic nephropathy is a main cause of chronic kidney disease (CKD) throughout the world, which requiring early detection and management. Anti-diabetic medications, like sodium-glucose cotransporter-2 (SGLT2) inhibitors, metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sulfonylurea compounds have determined various kidney protective efficacies; nevertheless, their effects on renal biomarkers remained disputing. Objectives: This study intended to assess renal function biomarkers, regarding anti-diabetic consumption, providing insights into their usefulness for risk categorization and management decision-making in diabetic nephropathy. Patients and Methods: This cross-sectional investigation, conducted in Basra Governorate, Iraq (October 2024–January 2025) with ethical approval from Basra University’s College of Pharmacy, enrolled participants to evaluate renal function biomarkers across antidiabetic medication regimens. Demographic and clinical data, including age, body mass index, gender, diabetes duration, hypertension status, and treatment regimen like metformin, sulfonylurea, DPP-4 inhibitors and SGLT-2 inhibitors, or combination therapies were gathered by interviews and clinical document reviews. In this study, fasting blood samples were analyzed for kidney function biomarkers, comprising serum creatinine, urea, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR). The study outcomes comprised comparing renal function biomarkers among antidiabetic medication regimens. Results: The study population comprised of 250 diabetes mellitus individuals (50.8% female) with a mean age of 55.67 ± 8.58 years. The findings showed considerable alterations of BUN, creatinine, urea and eGFR among the five groups. The individuals who received DPP-4 inhibitors had significantly higher BUN and urea levels than individuals treated with metformin or sulfonylurea monotherapy and higher serum creatinine concentration compared to metformin monotherapy, sulfonylurea monotherapy and combination therapy. Regarding eGFR, the DPP-4 inhibitor users had considerably lower value compared to all the other groups, both in metformin monotherapy, sulfonylurea monotherapy, and SGLT-2 inhibitor groups and also in patients under combination therapy. Conclusion: We found that the consequences of the antidiabetic drug therapy on kidney function are not the same. This study showed that DPP-4 cases had early indications of diminished kidney function than the individuals receiving metformin, sulfonylurea, SGLT-2, or a combination of them. This finding focuses on the importance of considering the potential impact on renal health in cases of selecting diabetes treatments.
- 28 February 2026
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 15 (3) , e27641
Open AccessComparative assessment of kidney function biomarkers related to anti-diabetic medication consumption; a cross-sectional analysis
Introduction: Diabetic nephropathy is a main cause of chronic kidney disease (CKD) throughout the world, which requiring early detection and management. Anti-diabetic medications, like sodium-glucose cotransporter-2 (SGLT2) inhibitors, metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sulfonylurea compounds have determined various kidney protective efficacies; nevertheless, their effects on renal biomarkers remained disputing. Objectives: This study intended to assess renal function biomarkers, regarding anti-diabetic consumption, providing insights into their usefulness for risk categorization and management decision-making in diabetic nephropathy. Patients and Methods: This cross-sectional investigation, conducted in Basra Governorate, Iraq (October 2024–January 2025) with ethical approval from Basra University’s College of Pharmacy, enrolled participants to evaluate renal function biomarkers across antidiabetic medication regimens. Demographic and clinical data, including age, body mass index, gender, diabetes duration, hypertension status, and treatment regimen like metformin, sulfonylurea, DPP-4 inhibitors and SGLT-2 inhibitors, or combination therapies were gathered by interviews and clinical document reviews. In this study, fasting blood samples were analyzed for kidney function biomarkers, comprising serum creatinine, urea, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR). The study outcomes comprised comparing renal function biomarkers among antidiabetic medication regimens. Results: The study population comprised of 250 diabetes mellitus individuals (50.8% female) with a mean age of 55.67 ± 8.58 years. The findings showed considerable alterations of BUN, creatinine, urea and eGFR among the five groups. The individuals who received DPP-4 inhibitors had significantly higher BUN and urea levels than individuals treated with metformin or sulfonylurea monotherapy and higher serum creatinine concentration compared to metformin monotherapy, sulfonylurea monotherapy and combination therapy. Regarding eGFR, the DPP-4 inhibitor users had considerably lower value compared to all the other groups, both in metformin monotherapy, sulfonylurea monotherapy, and SGLT-2 inhibitor groups and also in patients under combination therapy. Conclusion: We found that the consequences of the antidiabetic drug therapy on kidney function are not the same. This study showed that DPP-4 cases had early indications of diminished kidney function than the individuals receiving metformin, sulfonylurea, SGLT-2, or a combination of them. This finding focuses on the importance of considering the potential impact on renal health in cases of selecting diabetes treatments.
- Open Access
- 12 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-10
Activation of autophagy via bacterial lipopolysaccharide in breast cancer cells: A molecular approach to enhancing immunotherapeutic outcomes
Background : Autophagy plays a pivotal role in regulating cancer cell survival and death. Leveraging bacterial components, such as lipopolysaccharide (LPS), to modulate autophagy represents a novel strategy in oncologic therapeutics, especially in breast cancer. Objective : To assess the effect of LPS derived from Escherichia coli on the proliferation, viability, and immune signaling pathways in human breast cancer cell lines MCF-7 and MDA-MB-231, with a focus on autophagy induction and Toll-like receptor activation. Methods : LPS was isolated using the phenol–water method from E. coli strains ATCC 8739 and DH5α. Breast cancer cells were treated with varying concentrations of LPS over multiple time intervals (24–72 h). Viability was measured by MTT and CCK-8 assays, while mRNA expression levels of TLR-4, NF-κB, and PIK3C3 were quantified using qRT-PCR following RNA extraction and cDNA synthesis. Results : LPS treatment significantly reduced cell viability in both breast cancer cell lines in a time- and dose-dependent manner. Gene expression analysis revealed robust upregulation of TLR-4 and NF-κB, implicating activation of immune-related signaling. Moreover, increased PIK3C3 expression indicated stimulation of autophagic pathways. At the molecular level, there was an increase in the conversion of LC3-I to LC3-II and degradation of the autophagy substrate P62/SQSTM1, as confirmed by Western blot analysis, indicating enhanced autophagy. The findings confirm LPS’s ability to trigger immune–autophagic responses leading to cytotoxic effects in cancer cells. Conclusion : LPS from E. coli effectively induces autophagy and activates the immune pathway in breast cancer cells, highlighting its dual potential as an immunomodulator and cytotoxic agent. These findings support further exploration of LPS as an adjuvant in breast cancer treatment strategies, particularly in synergy with conventional chemotherapeutic agents.
- 12 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-10
Open AccessActivation of autophagy via bacterial lipopolysaccharide in breast cancer cells: A molecular approach to enhancing immunotherapeutic outcomes
Background : Autophagy plays a pivotal role in regulating cancer cell survival and death. Leveraging bacterial components, such as lipopolysaccharide (LPS), to modulate autophagy represents a novel strategy in oncologic therapeutics, especially in breast cancer. Objective : To assess the effect of LPS derived from Escherichia coli on the proliferation, viability, and immune signaling pathways in human breast cancer cell lines MCF-7 and MDA-MB-231, with a focus on autophagy induction and Toll-like receptor activation. Methods : LPS was isolated using the phenol–water method from E. coli strains ATCC 8739 and DH5α. Breast cancer cells were treated with varying concentrations of LPS over multiple time intervals (24–72 h). Viability was measured by MTT and CCK-8 assays, while mRNA expression levels of TLR-4, NF-κB, and PIK3C3 were quantified using qRT-PCR following RNA extraction and cDNA synthesis. Results : LPS treatment significantly reduced cell viability in both breast cancer cell lines in a time- and dose-dependent manner. Gene expression analysis revealed robust upregulation of TLR-4 and NF-κB, implicating activation of immune-related signaling. Moreover, increased PIK3C3 expression indicated stimulation of autophagic pathways. At the molecular level, there was an increase in the conversion of LC3-I to LC3-II and degradation of the autophagy substrate P62/SQSTM1, as confirmed by Western blot analysis, indicating enhanced autophagy. The findings confirm LPS’s ability to trigger immune–autophagic responses leading to cytotoxic effects in cancer cells. Conclusion : LPS from E. coli effectively induces autophagy and activates the immune pathway in breast cancer cells, highlighting its dual potential as an immunomodulator and cytotoxic agent. These findings support further exploration of LPS as an adjuvant in breast cancer treatment strategies, particularly in synergy with conventional chemotherapeutic agents.